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This weekly COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. 
1. Health Evidence Summary 
UK coronavirus crisis ‘to last until spring 2021 and could see 7.9 
million hospitalised’ 
Campbell D, Health policy editor | The Guardian | 15 March 2020 | News article 
https://www.theguardian.com/world/2020/mar/15/uk-coronavirus-crisis-to-last-until-spring-
2021-and-could-see-79m-hospitalised 
This media article covers a PHE briefing document, by the PHE’s emergency preparedness 
and response team and approved by PHE’s lead official dealing with the outbreak Dr Susan 
Hopkins, for senior NHS officials. The COVID-19 epidemic in the UK could circulate for another 
12 months lasting until next spring, infect as many as 80% of Britons, could lead to 7.9 million 
people being hospitalised (15%) and result in 531,100 deaths on the working assumption of a 
1% mortality rate. Prof Chris Whitty has previously described these figures as the worst-case-
scenario and that the mortality rate will be closer to 0.6%. The curve will peak at around the 
end of May to mid-June, drop for 10 weeks or more and possibly resurge in the autumn or 
winter months. This means planning for the long term will be necessary. 
 
Characteristics of pediatric SARS-CoV-2 infection and potential 
evidence for persistent fecal viral shedding 
Xu et al. | Nature Medicine | 13 March 2020 | Brief Communication 
https://www.nature.com/articles/s41591-020-0817-4 
Authors report on ten paediatric SARS-CoV-2 infection confirmed cases. Symptoms were 
nonspecific, no children required respiratory support or intensive care and there were no 
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definitive signs of pneumonia on chest X-rays, a defining feature of infection in adult cases. 
Authors suggest that fecal-oral transmission could be possible given that eight children 
persistently tested positive on rectal swabs even after naopharyngeal testing was negative.  
 
Detection of COVID-19 in children in early January 2020 in Wuhan, 
China 
Liu et al. | NEJM | 12 March 2020 | Correspondence 
https://www.nejm.org/doi/full/10.1056/NEJMc2003717 
In a retrospective study from 7 to 15 January 2020 SARS-CoV-2 was detected in 6 children 
(median age 3 years (range 1 to 7)) from a total of 366 hospitalised at three branches of Tongji 
Hospital in central Wuhan. All six children had a high fever (>39oC) and cough and four had 
vomiting. Four patients had pneumonia. One child was admitted to the paediatric intensive 
care unit and received pooled immune globulin from health donors. All patients were treated 
empirically with antiviral agents, antibiotic agents and supportive therapies. All recovered after 
hospitalisation for a median of 7.5 days (range 5 to 13). COVID-19 occurred in children early 
in the epidemic. 
 
LSTM researchers work on new diagnostics for COVID-19 
LSTM | 12 March 2020 | News article 
https://www.lstmed.ac.uk/news-events/news/lstm-researchers-work-on-new-diagnostics-for-
covid-19 
A team at LSTM is working with industry contacts to develop, evaluate and manufacture two 
point of care diagnostic tests for COVID-19 that can be carried out rapidly (results could be 
available in just 10 minutes), easily and in close to community settings and are suitable for 
implementation in low-middle income countries. Near-patient diagnostic capacity will help 
reduce transmission through effective triage of symptomatic patients and through infection 
control.  
 
The value of early transmission dynamic studies in emerging 
infectious diseases 
McBryde E | The Lancet Infectious Diseases | 11 March 2020 | Comment 
https://doi.org/10.1016/S1473-3099(20)30161-4 
Transmission dynamic models are a necessary first step in understanding the pandemic 
potential of an emerging infectious disease, including estimating the reproduction number (R0) 
– the number of new cases arising from a typical infected case. Many estimates of the 
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reproduction rate have appeared ranging from around 2 to more than 6. The study by Adam 
Kucharski and colleagues below addresses many assumptions of early works including a time-
varying reproduction number, showing the effect of the massive public health interventions put 
in place by China from 23 January 2020. 
 
There remains though urgent unanswered questions including the infectiousness of cases 
over the duration of their illness – particularly how much transmission could occur from people 
who are unaware that they have the illness, including asymptomatic and mildly symptomatic 
people, which will make disease much harder to detect and therefore control. What 
contribution such people make to the overall epidemic is unknown. Also, what the infection 
severity is, including the infection-fatality rate across different ages and risk group. Whilst early 
reports provide estimates of case fatality of 2.3% within China, it is “notoriously difficult to 
make such estimates early in an outbreak”. 
 
Ongoing modelling and surveillance should continue in mainland China and emerging foci 
outside of China, to determine if the reproduction ratio might vary in different climates and 
sociological contexts.  
 
Early dynamics of transmission and control of COVID-19: a 
mathematical modelling study 
Kucharski et al.  | The Lancet Infectious Diseases | 11 March 2020 | Article 
https://doi.org/10.1016/S1473-3099(20)30144-4 
This study combines available evidence from multiple data sources, reducing the dependency 
of their estimates on a single timepoint or dataset, to estimate how transmission has varied 
over time. The reproduction number began at 2.35 and fell to 1.05 during December 2019 and 
January 2020, coinciding with the unprecedented public health restrictions in China. Up to four 
imported cases may be required to establish transmission. This estimate assumes that SARS-
CoV-2 has similar heterogeneity of infectiousness to SARS-CoV, which was characterised by 
a number of super-spreaders with most cases infecting no other people, where multiple 
introductions might be required before an outbreak takes hold. Emerging evidence though is 
pointing to a more homogenous infectiousness profile of SARS-CoV-2 in which most people 
infect two to three others, where the risk of established local transmission with a single 
imported case is considerably higher.   
 
Are patients with hypertension and diabetes mellitus at increased 
risk for COVID-19 infection? 
Fang et al. | Lancet Respiratory Medicine | 11 March 2020 | Correspondence 
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https://www.thelancet.com/pdfs/journals/lanres/PIIS2213-2600(20)30116-8.pdf 
The most frequent comorbidities reported in three studies of patients with COVID-19 are often 
treated with angiotensin-converting enzyme (ACE) inhibitors. SARS-CoV-2 binds to their 
target cells through angiotensin-converting enzyme 2 (ACE2), which is expressed by epithelial 
cells of the lung, intestine, kidney and blood vessels. ACE2 expression is increased in diabetes 
and treatment with ACE inhibitors and angiotensin II type-I receptor blockers (ARBs) increases 
ACE2 expression, which could facilitate infection with COVID-19. The authors hypothesise 
that diabetes and hypertension treatment with ACE2-stimulating drugs increases the risk of 
developing severe and fatal COVID-19.  
 
The incubation period of COVID-19 from publicly reported 
confirmed cases: estimation and application 
Lauer et al. | Annals of Internal Medicine | 10 March 2020 | Article 
https://annals.org/aim/fullarticle/2762808/incubation-period-coronavirus-disease-2019-covid-
19-from-publicly-reported 
From pooled analysis of 181 confirmed COVID-19 cases reported between 4 January and 24 
February 2020  a median incubation period is estimated to be 5.1 days (95% CI 4.5 to 5.8 
days), similar to SARS, and 97.5% of those who develop symptoms will do so within 11.5 days 
(CI 8.2 to 15.6 days) of infection. Although publicly reported cases may overrepresent severe 
cases for which the incubation period may differ from that of mild cases, these results support 
current proposals for the length of quarantine or active monitoring of persons potentially 
exposed to SARS-CoV-2. Longer monitoring periods could be justified in extreme cases. 
 
The impact of COVID-19 in informal settlements – are we paying 
enough attention? 
Wilkinson A | IDS | 10 March 2020 | Opinion 
https://www.ids.ac.uk/opinions/the-impact-of-covid-19-in-informal-settlements-are-we-
paying-enough-attention/ 
What if you can’t wash your hands for 20 seconds and self-isolate if sick? One billion people 
live in slums or informational settlements where water for basic needs is in short supply and 
where space is constrained, and rooms are often shared. Discussion about vulnerability in 
these contexts has been startling absent. IDS, ESRC funded Sierra Leone Urban Research 
Centre (SLURC) and the GCRF funded hub on Accountability for Informal Urban Equity 
(ARISE) have been exploring how do residents organise to address existing health threats 
and how does this provide a basis for a COVID-19 response? 
 Data gaps: Data, especially for health, is often simply not collected so how do you 
develop preparedness and response plans if you do not even know the number of 
people living in an area? Response planners should engage with community-based 
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groups who do collect their own data to understand the realities and challenges of 
diseases control in slums. 
 Interdependences: Informal settlements and their residents are part of the city system, 
often subsiding and contributing to life elsewhere in the city making containment and 
reductions in movement control efforts difficult to implement. Slum-wide quarantines 
were ineffective with Ebola.  
 Inequalities and vulnerabilities: People rely on informal health providers as a first port 
of call, especially for fevers and coughs. These providers should be included in 
pandemic response plans and could detect early cases. Health systems in informal 
settlements are limited. Older people can be relatively isolated, especially childless 
women or widows. There may be pockets of highly vulnerable and isolated people – 
the old and those with co-morbidities without support and unable to access care. 
 Community engagement: Delivering trusted messages, carrying out surveillance, or 
attempting to limit movement must engagement the community to be effective. There 
is no simple answer though to who people trust and what a ‘community’ is in these 
contexts. An effective leader could be a chief or councillor, businessperson, traditional 
healer, member of a youth group or even a gang leader. Working with the community-
based groups that already exit to respond to repeated disasters – cholera, fires, 
flooding and mudslides – will be key. 
There is a real risk that the COVID-19 “impacts on the urban poor will be considerably higher 
than elsewhere”. To mitigate these impacts and to achieve longer-term changes in urban 
planning, the discussion needs to change from responding to COVID-19 in universal terms to 
how to improve the way we see, understand and address heath and living conditions in 
informal settlements.  
 
Clinical course and risk factors for mortality of adult inpatients with 
COVID-19 in Wuhan, China: a retrospective cohort study 
Zhou et al. | The Lancet | 9 March 2020 | Article 
https://doi.org/10.1016/S0140-6736(20)30566-3 
In this retrospective multicentre cohort study of 191 adult (18 years or older) inpatients in two 
hospitals in Wuhan, China assessing risk factors of mortality for adult patients with COVID-
19, authors found that increasing odds of in-hospital death was associated with older age, 
high Sequential Organ Failure Assessment (SOFA) score and d-dimer levels greater than 1.0 
ug/mL on admission. The most common comorbidity was hypertension (91 (48%) patients), 
followed by diabetes (36 (19%) patients) and coronary heart diseases (15 (8%) patients). 
Duration of viral shedding ranged between 8 and 37 days. The median duration of viral 
shedding was 20.0 days (IQR 17.0 to 24.0) in survivors but continued until death in fatal cases. 
Older age, elevated d-dimer levels and high SOFA score could help clinicians to identify at an 
early stage those patients with COVID-19 who have poor prognosis. Prolonged viral shedding 
provides the rationale for a strategy of isolation of infected patients. 
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A coordinated Global Research Roadmap: R&D blueprint 
WHO | 4 March 2020 | R&D blueprint 
https://www.who.int/blueprint/priority-diseases/key-action/Roadmap-version-FINAL-for-
WEB.pdf?ua=1 
This document presents critical research questions that need to be answered urgently; 
immediate, mid-term and longer-term priorities for a global research response; and ways to 
work together to accelerate and fund priority research that can curtail the COVID-19 outbreak 
and prepare for future outbreaks. This document was produced based on the Global Research 
and Innovation Forum of world scientists at WHO Geneva from 11 to 12 February 2020.  The 
latest reports on vaccines, therapeutics, diagnostics and Global Coordination Mechanism can 
be found here 
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/ 
 
Strategic preparedness and response plan for the new coronavirus 
WHO | 3 February 2020 | Response plan 
https://www.who.int/publications-detail/strategic-preparedness-and-response-plan-for-the-
new-coronavirus 
This plan outlines public health measures that the international community can provide to 
support all countries to prepare and respond to COVID-19. The document provides strategic 
action to guide national and international partners when developing context-specific national 
and regional operational plans. 
2. Tracking COVID-19 cases 
Global 
WHO COVID-19 daily situation reports 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports 
An interactive web-based dashboard to track COVID-19 in real time 
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd4029942
3467b48e9ecf6 
COVID-19: PHE track coronavirus cases in the UK 
https://www.gov.uk/government/publications/covid-19-track-coronavirus-cases 
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UK case tracing infographic 
https://www.arcgis.com/apps/opsdashboard/index.html#/f94c3c90da5b4e9f9a0b19484dd4b
b14 
3. Online course 
COVID-19: Tackling the Novel Coronavirus 
LSHTM | FutureLearn course | Starts 23 March 2020 | 3 weeks | 4 hours weekly study | Free 
https://www.futurelearn.com/courses/covid19-novel-coronavirus 
On this course you will learn what is known about the outbreak of COVID-19 (week 1); what 
the practical implications for responding to COVID-19 are (week 2); and what we need to find 
out about COVID-19 (week 3). 
4. Funding 
WHO, UN Foundation and partners launch first-of-its-kind COVID-19 Solidarity Response 
Fund 
WHO | 13 March 2020 | News release 
https://www.who.int/news-room/detail/13-03-2020-who-un-foundation-and-partners-launch-
first-of-its-kind-covid-19-solidarity-response-fund 
This new Fund will raise money from a wide range of donors, including private individuals, 
corporations and institutes anywhere, to support the work of the WHO and partners implement 
the COVID-19 Strategic Preparedness and Response Plan to enable all countries to prepare 
for and respond to the COVID-19 crises and in particular those most vulnerable and at-risk, 
and with the weakest health systems. 
5. Resource Hubs 
Global research on COVID-19 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-
coronavirus-2019-ncovnovel-coronavirus-2019-ncov 
WHO R&D Blueprint 
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/ 
WHO: Coronavirus disease (COVID-19) outbreak resources 
https://www.who.int/emergencies/diseases/novel-coronavirus-2019 
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Latest information and advice from the UK Government 
https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public 
CDC COVID-19 Resources 
https://www.cdc.gov/coronavirus/2019-ncov/index.html 
The Global Health Network Coronavirus outbreak knowledge hub 
https://coronavirus.tghn.org 
The Lancet COVID-19 Resource Centre 
https://www.thelancet.com/coronavirus 
Elsevier’s Novel Coronavirus Information Center 
https://www.elsevier.com/connect/coronavirus-information-center 
Cell Press Coronavirus Resource Hub 
https://www.cell.com/2019-nCOV 
Cochrane Special Collections - COVID-19: infection control and prevention measures 
https://www.cochranelibrary.com/collections/doi/SC000040/full 
The BMJ Coronavirus (covid-19): Latest news and resources 
https://www.bmj.com/coronavirus?int_source=wisepops&int_medium=wisepops&int_campai
gn=DAA_CoronaVirus_Jan24 
Johns Hopkins Coronavirus Resource Centre 
https://coronavirus.jhu.edu 
And finally, for now… 
There is discussion about changing the term “social distancing” to “physical distancing” 
#PhysicalDistancing #SocialDistancing  
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